Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Reaffirmed as Buy by HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright‘s target price indicates a potential upside of 321.61% from the company’s previous close.

ACRS has been the topic of several other reports. Canaccord Genuity Group began coverage on Aclaris Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Finally, Wall Street Zen upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aclaris Therapeutics has an average rating of “Buy” and an average price target of $11.11.

Aclaris Therapeutics Stock Up 0.1%

Shares of ACRS traded up $0.01 during midday trading on Wednesday, reaching $3.80. 362,749 shares of the stock were exchanged, compared to its average volume of 2,217,392. The business’s 50-day moving average price is $5.02 and its 200 day moving average price is $4.50. Aclaris Therapeutics has a twelve month low of $2.10 and a twelve month high of $6.60.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $1.38 million. Analysts anticipate that Aclaris Therapeutics will post -0.62 EPS for the current year.

Institutional Investors Weigh In On Aclaris Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Aclaris Therapeutics by 20.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 26,858 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 4,630 shares during the period. MBE Wealth Management LLC acquired a new stake in shares of Aclaris Therapeutics during the third quarter worth $53,000. Braidwell LP grew its holdings in Aclaris Therapeutics by 26.1% in the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company’s stock worth $11,333,000 after purchasing an additional 443,232 shares during the period. Wellington Management Group LLP grew its holdings in Aclaris Therapeutics by 4.0% in the second quarter. Wellington Management Group LLP now owns 267,498 shares of the biotechnology company’s stock worth $1,415,000 after purchasing an additional 10,342 shares during the period. Finally, Palo Alto Investors LP bought a new position in shares of Aclaris Therapeutics in the second quarter valued at $8,535,045. 98.34% of the stock is owned by institutional investors.

Key Headlines Impacting Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: Aclaris reported positive Phase 1b proof-of-concept results for ATI-052, its anti-TSLP/IL-4Rα bispecific candidate, in atopic dermatitis and asthma. The update supports the potential of Aclaris’ immuno-inflammatory pipeline and provides an important early clinical validation. Aclaris ATI-052 Phase 1b Results
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $16 price target, implying substantial upside from recent trading levels. The bullish view suggests the firm sees meaningful value in ATI-052 and Aclaris’ broader pipeline.
• Neutral Sentiment: Wedbush reduced its price target from $10 to $8 but maintained an “outperform” rating. Although the lower target is a more cautious valuation signal, the rating remains positive.
• Neutral Sentiment: Reported short interest was zero as of October 26, indicating little evidence of active short-selling pressure, though this data is unlikely to be a major near-term catalyst.
• Negative Sentiment: Aclaris priced a $50 million underwritten offering consisting of 7.79 million common shares at $3.50 per share and pre-funded warrants for approximately 6.5 million additional shares. The financing strengthens the balance sheet and funds development, but the large number of new potential shares creates significant dilution and the offering price may weigh on the stock. Aclaris $50 Million Offering

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company’s research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris’ lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.